Drug Insight: different mechanisms of action of tumor necrosis factor antagonists—passive-aggressive behavior?

被引：0
|
作者：
William FC Rigby
机构：
[1] WFC Rigby is a Professor of Medicine,
[2] Microbiology and Immunology at Dartmouth Medical School,undefined
[3] Lebanon,undefined
[4] NH,undefined
[5] USA.,undefined
来源：
Nature Clinical Practice Rheumatology | 2007年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Etanercept, adalimumab and infliximab all specifically antagonize tumor necrosis factor (TNF), but with differential clinical efficacy. Differences in their pharmacology and mechanisms of action, and disease heterogeneity, might account for this therapeutic disparity, as might reverse signaling by transmembrane TNF in response to anti-TNF antibodies, all of which are reviewed here.
引用
收藏
页码：227 / 233
页数：6
相关论文
共 50 条
  • [21] BIOLOGIC ACTIVITIES AND MECHANISMS OF ACTION OF TUMOR-NECROSIS-FACTOR-ALPHA CACHECTIN
    JAATTELA, M
    LABORATORY INVESTIGATION, 1991, 64 (06) : 724 - 742
  • [22] The Risk of Drug-Induced Liver Injury From Tumor Necrosis Factor (TNF)-α Antagonists
    Gunnarsson, Baldvin I.
    Grondal, Gerdur
    Ludviksson, Bjorn R.
    Einarsdottir, Rannveig
    Olafsson, Sigurdur
    Jonasson, Jon G.
    Bjornsson, Einar
    GASTROENTEROLOGY, 2014, 146 (05) : S910 - S910
  • [23] Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis
    Marcia L Moss
    Liora Sklair-Tavron
    Raphael Nudelman
    Nature Clinical Practice Rheumatology, 2008, 4 : 300 - 309
  • [24] Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis
    Moss, Marcia L.
    Sklair-Tavron, Liora
    Nudelman, Raphael
    NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2008, 4 (06): : 300 - 309
  • [25] TUMOR NECROSIS FACTOR-ALPHA ANTAGONISTS: DIFFERENTIAL CLINICAL EFFECTS BY DIFFERENT BIOTECHNOLOGICAL MOLECULES
    Licastro, F.
    Chiappelli, M.
    Ianni, M.
    Porcellini, E.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2009, 22 (03) : 567 - 572
  • [26] Differences in Fc receptor and C1q binding in tumor necrosis factor (TNF) antagonists may contribute to differences in mechanisms of action
    Kohno, T
    Louie, JS
    Stevens, SR
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 124 (04) : A111 - A111
  • [27] Mechanisms of Action of Anti-tumor Necrosis Factor a Agents in Crohn's Disease
    Peake, Simon T. C.
    Bernardo, David
    Mann, Elizabeth R.
    Al-Hassi, Hafid O.
    Knight, Stella C.
    Hart, Ailsa L.
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (07) : 1546 - 1555
  • [28] MECHANISMS OF ACTION OF THE TUMOR-NECROSIS-FACTOR AND LYMPHOTOXIN LIGAND-RECEPTOR SYSTEM
    WARZOCHA, K
    BIENVENU, J
    COIFFIER, B
    SALLES, G
    EUROPEAN CYTOKINE NETWORK, 1995, 6 (02) : 83 - 96
  • [29] Different tumor necrosis factor α antagonists have different effects on host susceptibility to disseminated and oropharyngeal candidiasis in mice
    Park, Hyunsook
    Solis, Norma V.
    Louie, James S.
    Spellberg, Brad
    Rodriguez, Natalie
    Filler, Scott G.
    VIRULENCE, 2014, 5 (05) : 625 - 629
  • [30] Binding site analyses of human tumor necrosis factor-alpha antagonists elucidate their neutralizing mechanisms
    Kim, Min-Soo
    Song, Moo-Young
    Lee, Byung-Kyu
    Kim, Yong-Sung
    JOURNAL OF BIOTECHNOLOGY, 2007, 131 (02) : S256 - S256
12345